We advised the joint book-running managers on the offering

Davis Polk advised the joint book-running managers in connection with the $125 million offering of 55,555,556 shares of common stock of Editas Medicine, Inc. and accompanying warrants to purchase up to 55,555,556 shares of common stock (or pre-funded warrants in lieu of common stock) of Editas Medicine, Inc.

As a pioneering gene editing company, Editas Medicine is focused on translating the power and potential of CRISPR genome editing systems into a robust pipeline of transformative in vivo medicines for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture and commercialize durable, precision in vivo gene editing medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute’s Cas12a patent estate and Broad Institute and Harvard University’s Cas9 patent estates for human medicines.

The Davis Polk corporate team included partners Richard D. Truesdell Jr. and Yasin Keshvargar and counsel Michael Stromquist. Partner David R. Bauer and associates Bari Britvan and Daniella Martino provided intellectual property advice. The tax team included partner Kara L. Mungovan and associate Omar Hersi. All members of the Davis Polk team are based in the New York office.

Copy link to share post